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Transitioning to human trials from pre-clinical models resulted in the emergence of inhibitory
AAV vector immune responses which has become a hurdle for sustained correction. Early
animal studies did not predict the full range of host immunity to the AAV vector in human
studies. While pre-existing antibody titers against AAV vectors has been a lingering con-
cern, cytotoxicT-cell (CTL) responses against the input capsid can prevent long-term therapy
in humans. These discoveries spawned more thorough profiling of immune response to
rAAV in pre-clinical models, which have assessed both innate and adaptive immunity and
explored methods for bypassing these responses. Many efforts toward measuring innate
immunity have utilized Toll-like receptor deficient models and have focused on differen-
tial responses to viral capsid and genome. From adaptive studies, it is clear that humoral
responses are relevant for initial vector transduction efficiency while cellular responses
impact long-term outcomes of gene transfer. Measuring humoral responses to AAV vec-
tors has utilized in vitro neutralizing antibody assays and transfer of seropositive serum
to immunodeficient mice. Overcoming antibodies using CD20 inhibitors, plasmapheresis,
altering route of delivery and using different capsids have been explored. CTL responses
were measured using in vitro and in vivo models. In in vitro assays expansion of antigen-
specific T-cells as well as cytotoxicity toward AAV transduced cells can be shown. Many
groups have successfully mimicked antigen-specific T-cell proliferation, but actual trans-
gene level reduction and parameters of cytotoxicity toward transduced target cells have
only been shown in one model. The model utilized adoptive transfer of capsid-specific
in vitro expanded T-cells isolated from immunized mice with LPS as an adjuvant. Finally,
the development of immune tolerance to AAV vectors by enriching regulatory T-cells as
well as modulating the response pharmacologically has also been explored.
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INTRODUCTION
Over the past 20 years, a full spectrum of immune responses
to AAV has been assessed to include innate responses, humoral
responses, and T-cell responses. In addition to the emphasis on
pre-existing antibodies to AAV, cytotoxic T-cell (CTL) responses to
AAV have emerged as a challenge for clinical applications. Roughly
70% of the human population has neutralizing antibodies (NAb)
titers to AAV2 that can interfere with gene therapy (1–4). The use
of different AAV capsids may overcome this challenge yet lower
antibody titers to alternative capsids as well as cross-reactivity of
AAV2 antibodies is concerning (3, 4).
Since mice and dogs do not have pre-existing immunity to AAV,
correction in coagulation actor IX (FIX) deficient animal stud-
ies have been sustained without concern of immune responses
(5–7). Unfortunately, the lack of immunity in pre-clinical stud-
ies did not fully reflect clinical results. In patient studies using
AAV2 or AAV8 expressing normal or self-complimentary (sc) hFIX
respectively, AAV1 expressing α1-antityrpsin (AAT), and Lipopro-
tein Lipase (LPL) correction, capsid-specific CTL responses have
emerged, particularly at high doses (8–11). In some cases, existence
of capsid-specific CTLs did not significantly impact correction as
seen in AAT studies involving intramuscular (IM) injections (10).
In hemophilia B (HB) liver studies, correction at 10% of normal
was achieved in high dose cohorts. This level was only sustained 4–
8 weeks and a spike in liver transaminases coincided with a drop in
hFIX levels (8, 9), which was coordinated by capsid-specific CTLs.
With the occurrence of CTL responses and presence of pre-existing
antibodies to AAV capsid there has been a concerted effort to
develop suitable pre-clinical approaches for complete assessment
of immune responses and to develop intervention techniques.
CHARACTERIZATION OF INNATE IMMUNITY TO AAV
Pattern recognition receptors (PRRs) on monocytes recognize
AAV particles and trigger innate immunity (12–15). TLR2 and
TLR9 have been identified as the PRRs for AAV. TLR2 triggers
responses to the capsid while TLR9 detects the viral genome.
Studies have been performed in myeloid differentiation primary
response 88 (myd88−/−), tlr9−/− and tlr2−/− deficient mice to
pinpoint TLR pathways associated with AAV recognition. Addi-
tionally, adaptive responses have been assessed in these mice.
Moreover, studies were performed in interferon β receptor of KO
mice (ifnr−/−) to establish a cytokine for developing adaptive
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responses (13, 14). Measuring cytokine secretion from differenti-
ated monocytes isolated from these KO mice was used to segregate
responses to AAV2. Absence of type I interferon (IFN) responses in
AAV-activated plasmacytoid dendritic cells (pDCs) isolated from
tlr9−/− mice as well as myd88−/− but not trl2−/− mice sug-
gests that IFN responses are due to the vector genome, not the
capsid (12–14).
To further assess the immune responses to AAV in KO mice,
cellular and humoral responses were measured. Assessing NAbs,
serum IgG2a or CTL responses to AAV capsid in mice deficient
in innate immunity was used to determine a pathogen recogni-
tion link between innate and adaptive response. Both tlr9−/−
and myd88−/− mice showed absence of adaptive responses to
AAV (13, 14). AAV antibody titers were assessed by enzyme-linked
immunosorbent assay (ELISA) while CTL responses were assessed
using enzyme-linked immunosorbent spot (ELISpot) analysis of
IFN-γ secretion from isolated splenocytes.
Efforts to determine if genome or capsid modifications alter
innate responses have been pursued. Gene expression in liver of
AAV2-infected mice showed an increase in inflammatory medi-
ators and TLR9 transcripts, but not TLR2. Additionally, the
responses remained the same between capsid variants but the
sc genome resulted in a significant increase in transcription of
inflammatory mediators. Determining cellular recruitment also
indicated the sc-genome significantly increased inflammation.
This was measured by staining liver sections for neutrophils,
Mac-1+ macrophages and cd335+ natural killer cells. The use
of tlr9−/− mice as well as TLR9 antagonists prevented innate
immune responses, showed a reduction in adaptive immunity,
and demonstrated a plausible connection between TLR9 and
development of antibodies and CTLs (14).
Efforts to isolate immune responses to AAV input capsid have
also been performed. TLR2 and TLR4 are highly associated with
recognition of viral structural proteins (16). The production of
empty capsids devoid of genomes and the use of HEK293 reporter
cell lines, which secrete IL-8 due to activation of stably expressed
TLR2 or TLR9, have aided in pinpointing PRRs associated with
capsid. HEK293/TLR2 but not HEK293/TLR9 showed activation
by empty vectors (15).
HUMORAL IMMUNITY
Epidemiology studies have predicted that ~70% of the population
is seropositive for AAV2 (1–4). Further studies have estimated a
lower degree of seroprevalence for other AAV capsids (4). More-
over, 20–40% of the population has NAb titers (1:80) against AAV2
capable of reducing transduction of Huh7 cultured cells by 50%
using a Multiplicity of Infection of 104. Additionally, the ability
of AAV2 NAb to reduce transduction efficiency against alternative
serotypes has developed concern for cross-reactivity.
CHARACTERIZING NAb INHIBITION OF AAV
Dot Blot studies, NAb assays and cross administration of AAV
vectors in animals have been used to determine cross-reactivity
of AAV antibodies. The cross-reactivity of αAAV1 or αAAV5 anti-
bodies was tested against a dot blot containing AAV1,AAV2,AAV4,
AAV5, AAV6, AAV7, AAV8, AAV9 capsid. AAV1 antibodies showed
strong adherence to only AAV6, while AAV5 antibodies had
minimal adherence to AAV1 (17) and only at high concentrations
of monoclonal antibodies.
In NAb in vitro assays, AAV vectors are pre-incubated with
serum containing NAbs prior to infection of cultured cells and
can be used for assessing cross-reactivity when alternative capsids
are selected. Using this assay, it was determined that NAbs against
AAV1 or AAV5 had limited impact on transduction from the other
capsid. Additionally, engineered capsid modifications to AAV2 or
a chimeric AAV capsid overcame antibody neutralization based on
parental AAV antigens (4, 17–19).
Neutralizing antibody in mice also determined the potential
of AAV antibodies to cross react with a different capsid using
in vivo approaches. Mice were pre-immunized by IM injection of
AAV2/GFP then challenged with AAV1, AAV3, AAV4, and AAV5
(20). Data showed that AAV2 antibodies only neutralized AAV3.
Another model used an intravenous (IV) infusion in mice of AAV2
immunoglobulin from a pool of individual human donors prior
to liver delivery of AAV2, AAV6 or AAV8 expressing hFIX. AAV2
administration was completely blocked while AAV6 and AAV8
were partially blocked (18). Given that the immunoglobulin pool
was not assessed for AAV6 or AAV8 antibodies the results seen may
not have been due to cross-reactivity.
OVERCOMING HUMORAL RESPONSES TO AAV VECTORS
A comparative approach to test the ideal route of administration to
overcome pre-existing NAbs in mice involved an initial IV infusion
of AAV2 immunoglobulin from a collection of AAV2 seropostive
serum prior to administrating AAV2 via different routes. Delivery
of AAV2 to liver by portal vein or direct injection into the liver
parenchyma showed successful transduction in the face of pre-
existing AAV2 antibodies prophylaxis, while IV injection did not
(21). It should be noted that even direct administration of vector
to the liver resulted in lower expression levels in the presence of
NAb, indicating that even this approach is not able to completely
bypass Nab inhibition.
Manipulating the capsid is another approach to overcome
NAbs. Generation of alternative capsid libraries by rational muta-
tions in antigenic regions (22), error prone PCR (23), and DNA
shuffling (24) have demonstrated the potential. PEGylation is a
chemical modification which involves pre-coating the AAV capsid
with polyethylene glycol (PEG) prior to administration and has
shown promise at limiting but not preventing neutralization (25,
26). Another promising strategy involves artificially encapsulating
the AAV vector in biomaterial prior to administration which has
the potential to shield the AAV capsid (27). This may be useful pro-
vided the biomaterial cloak can be degraded after delivery. While
these approaches are encouraging they may limit transduction
efficiency.
Temporary immunosuppresion (IS) is emerging as a preferred
approach for overcoming humoral responses and has been tested
in pre-clinical studies. The inhibition of helper T-cells using CD4
antibodies or cyclosporine A prevents NAb formation and facili-
tates vector readministration (28). Additionally, transient B-cell
depletion using Rituximab (CD20 antibody) can reduce pre-
existing antibodies (29). Plasmapheresis can eliminate pre-existing
humoral responses but requires multiple cycles of blood exchange
to reduce NAbs to negligible levels (30). Similarly, flushing the
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macaque liver with saline prior to delivery of vector limited
NAb inhibition (31). In an ongoing clinical trial, empty capsids
were added to the vector with the rational that they will bind
away Nabs and thus increase transgene expression (32). However
this approach involves increasing vector load, which may not be
favorable for trying to prevent the development of CTL responses.
CHARACTERIZING INHIBITORY CTL RESPONSES TO AAV IN
PRE-CLINICAL STUDIES
The first CTL response with parenchymal damage, loss of trans-
gene expression, and expansion of capsid-specific CTLs were
observed during a liver directed clinical trial for HB. This was
unexpected since it was not observed in pre-clinical studies includ-
ing non-human primates. Early attempts to replicate this immune
response in animals were unsuccessful (33, 34). Even dog models
have shown consistent transgene expression without an immune
response (5). Therefore, efforts were made to determine varia-
tions in immunity between humans and pre-clinical animals. The
absence of CTL responses in non-human primates, which are nat-
ural hosts of AAV8, ruled out the expansion of memory T-cells as
the contributing factor (35, 36). Varki and colleagues reported the
loss of siglec receptor expression in T lymphocytes during human
evolution (37). Siglec receptors have inhibitory function on the
immune system. Exploring the loss of these inhibitory receptors
as a possible reason revealed enhanced T-cell function in a mouse
KO model which mimics human T-cells, suggesting that human
T-cells respond with more activation and proliferation (38). How-
ever, the response to AAV also could not be induced in these KO
mouse.
In trying to develop CTL responses in pre-clinical animal mod-
els, one approach delivered a rAAV expressing IL-12 to the liver
(39). Despite the induction of liver inflammation and generation
of capsid-specific CTLs, transduced hepatocytes were not elim-
inated. Another model used an immunogenic OVA/SIINFEKL
mouse system. The OT-1 mouse line has an increased frequency
of OVA SIINFEKL epitope-specific CTLs. The model requires
immunization of OT-1 mice with Ad-AAV. Splenocytes were har-
vested, labeled with carboxyfluorescein succinimidyl ester (cfse),
and adoptively transferred into mice injected with an AAV vec-
tor with the SIINFEKL epitope incorporated into the capsid (40).
Prolonged proliferation of OT-1 transferred cells (at least 10 weeks
after transfer) was observed compared to transfer of wt splenocytes
from Ad-AAV immunized mice, however no parenchymal cyto-
toxicity was reported. The Samulski lab also used the SIINFEKL
mouse system. They discovered reduced transgene expression after
adoptive transfer of OT-1 splenocytes however only in AAV-treated
mice pre-immunized with SIINFEKL-pulsed DCs. Unfortunately,
this approach is not ideal given the high immunogenicity, which
might not fully reflect actual immunity (41).
IN VITRO ASSAYS FOR CHARACTERIZING CTLs
In vitro assays have had more success at characterizing AAV cap-
sid CTL development and involve monitoring CTL activation and
cytotoxicity in response to peptide presentation of AAV capsids
in target cells. It is possible to detect AAV capsid-specific CTLs
by staining with a multimeric antibody. However staining with
these multimers only detects single T-cell clones and is HLA
restrictive. As a result, T-cells only from individuals who express a
specific HLA type can be visualized. An engineered cell line, which
expresses luciferase upon engagement of a specific T-cell receptor
was used to monitor T-cells activation (42). Again, this assay is
restricted to one HLA type (HLAB0702) and AAV2 recognition. A
more flexible assay measures cytotoxicity toward AAV-transduced
hepatocytes. In this assay, different serotypes can be tested as long
as they transduce the target cells (43, 44). Briefly, CTLs are gener-
ated by several rounds of stimulation and proliferation of target
cell HLA matched peripheral blood mononuclear cells (PBMCs)
or spenocytes with the AAV serotype of interest or dominant epi-
tope and then co-cultured with target cells that are transduced
with that AAV and cytotoxicity is measured. In general, a major
limitation of in vitro assays is the fact that transduction efficiency
of alternate AAV serotypes differs significantly and hinders com-
parative studies between alternate capsid variants and serotypes.
Still these assays are helpful in monitoring CTLs responses in mice
and in PBMCs obtained during clinical trials.
VECTOR CAPSID VARIATIONS FOR AVOIDING CTL
RESPONSES
There is a growing field of vector alterations to increase efficiency
and avoid immunity. The rational for creating capsid mutants
differs among groups, however most target tyrosine and serine
residues on the AAV capsid to enhance transduction efficiency.
The Srivastava lab (45) has reported a triple tyrosine capsid
mutant with increased transduction efficiency in vitro and in vivo.
Other groups also report increased transduction efficiency by
altering tyrosine residues on the AAV capsid (46). Initial data sug-
gests that increased transgene expression is likely due to reduced
proteasomal degradation which will shuttle more vector to the
nucleus, but the intracellular trafficking of vector has not been
fully characterized.
From an immunological perspective, avoiding proteasomal
degradation may also lead to reduced CTL recognition. Tyro-
sine mutants were tested in an immunological mouse model and
the group reported increased transgene expression and showed
reduced T-cell immunogenicity and toxicity within the liver (44).
To mimic the cellular immune reaction in humans, the group
adoptively transferred in vitro expanded CTLs from AAV immu-
nized mice. In this setting, they were able to demonstrate cyto-
toxicity in the liver by reduction of transgene levels and increased
liver enzymes, both of which were reversed when using the capsid
mutant.
PHARMACOLOGICAL INTERVENTION
General IS (taken from treatment of autoimmune disorders or
transplantations) (9) and more specific interventions for AAV have
been proposed and tested in pre-clinical models, such as proteaso-
mal inhibitors (PI) (e.g., bortezomib, MG 132, carfilzomib). Many
groups focus on increasing AAV transduction levels in various
tissues using PI (47–50), and other compounds like arsenic triox-
ide (51), rather than their influence on the immune response. At
the same time, another group observed reduced CTL responses
as well (42). The mechanism is not completely understood yet it
is hypothesized that AAV proteasomal capsid degradation is dis-
rupted which leads to diminished capsid–peptide presentation by
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MHC class I molecules. This intervention has only been tested in
pre-clinical systems for mechanistic value, given that the later fate
of undigested capsids is unknown and could present the danger of
prolonged or delayed capsid–peptide presentation.
DEVELOPING TOLERANCE
Multiple groups have demonstrated induced tolerance to the trans-
gene for hepatic delivery of AAV vectors with the involvement
of regulatory T-cells (Tregs) (52–55). Attempts to induce toler-
ance to the AAV capsid through the enrichment of Tregs have
been published and show promising results. Initially, De Groot
and colleagues were able to show reduced immune responses to
common immunogens in vitro and in vivo using MHC class II
epitopes (Tregitopes) that favor Treg development (56). These
observations were extended to AAV capsid tolerance in a sub-
sequent study (57). They show AAV capsid CTL suppression using
these Tregitopes.
CONCLUSION
Due to the combined efforts of multiple groups working on the
various aspects of immune responses to gene delivery with a
rAAV vector, many parameters have been deciphered. For humoral
immune response models, various models have been established to
characterize pre-existing humoral immunity and cross-reactivity
and assess the impact of potential interventions in vitro and in vivo.
Using pre-existing KO mice, the influence of the innate immune
system is also being rapidly investigated. In contrast, finding mod-
els to mimic and investigate the cellular immune response toward
AAV capsids has caused more difficulty, only robust in vitro mod-
els have been well established but recently some features of the
response could be recapitulated in animal models. It remains to be
seen if these approaches will be able to provide a sufficient platform
for further deciphering of cellular immune response and testing
interventions. While characterizing immune responses in animal
models have been informative, it is evident that greater emphasis
should be placed on developing CTL models in immunocompe-
tent animals that are more reflective of the clinical scenario. Until
reliable models are established, investigators can use the valuable
published data gathered in human clinical trials about cellular
immune responses and their management (8, 9).
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